New Programs Track Off-Label Use of Targeted Cancer Drugs

Two programs are underway to track off-label use of targeted cancer drugs and patient outcomes, as well as facilitate patient access to these agents. According to Nature News, more than 60% of US prescriptions for cancer drugs are for off-label use—often because patients have a tumor with a feature or

Read more

New Ways to Treat HCV Infection After Liver Transplant

New direct-acting agents against hepatitis C virus (HCV) can cure the infection when it recurs in patients with liver transplants. Researchers reported findings from 3 separate studies at the 65th Annual Meeting of the American Association for the Study of Liver Diseases last week in Boston. HCV is the leading

Read more
  • Video: Risk of Upper Gastrointestinal Bleeding From Different Drug Combinations

Video: Risk of Upper Gastrointestinal Bleeding From Different Drug Combinations

Combined use of nonselective nonsteroidal anti-inflammatory drugs (nNSAIDs), COX-2 selective inhibitors, or low-dose aspirin with selective serotonin reuptake inhibitors significantly increases the risk of upper gastrointestinal (GI) bleeding, researchers report in the October issue of Gastroenterology. In their case series analysis of data from 114,835 patients with upper GI bleeding (930,888 person-years of follow-up),

Read more

Podcast: Efficacy of Vedolizumab in Patients with Moderately to Severely Active Crohn’s disease

Listen to Bruce Sands discuss his article in the September issue of Gastroenterology discussing results from placebo-controlled, phase 3 double-blind trial of the efficacy of vedolizumab  in patients with moderately to severely active Crohn’s disease, including those for whom previous anti-TNF treatment had failed. Sands et al. report that vedolizumab, an antibody against the integrin α4β7, is no more effective

Read more
  • How Do NS5A Inhibitors Prevent HCV Replication?

How Do NS5A Inhibitors Prevent HCV Replication?

Researchers have uncovered the mechanisms of drugs that inhibit the hepatitis C virus (HCV) non-structural protein 5A (NS5A), described in the August issue of Gastroenterology. In a quantitative analysis of the kinetics of NS5A inhibitors, David R. McGivern et al.  show that these agents rapidly inhibit intracellular assembly of virions and

Read more
  • Does Cancer Treatment Bring Back HCV Infection?

Does Cancer Treatment Bring Back HCV Infection?

Treated hepatitis C virus (HCV) infections do not return after patients receive chemotherapy or immunosuppressive therapy, researchers report in the June issue of Clinical Gastroenterology and Hepatology. Cancer chemotherapy leads to HCV reactivation in patients with chronic infections, but little is known about the effect of chemotherapy on HCV infections

Read more
  • What is the Best Way to Care for Patients with Alcoholic Hepatitis?

What is the Best Way to Care for Patients with Alcoholic Hepatitis?

Although alcohol-related liver disease is the 8th most common cause of mortality in the US and the 2nd leading cause of mortality among all gastrointestinal diseases, there are few therapeutic options for patients or resources to support identification of new therapies. However, treatment approaches are being developed; a review in

Read more

Are IBD Drugs Safe During Pregnancy?

Researchers find no evidence that inflammatory bowel disease (IBD) during pregnancy, or medical treatment for IBD during pregnancy, increases risk for congenital abnormalities in children. The findings, based on a large database analysis, are published in the January issue of Gastroenterology. IBD frequently affects women of reproductive age, and is often

Read more

Putting a Cap on Acid Reflux

Researchers show that a polysaccharide ‘raft’ can float on top of acid in the stomach to block its backflow into the esophagus. It reduces reflux symptoms in patients with gastroesophageal reflux disease (GERD), according to a clinical trial the December issue of Clinical Gastroenterology and Hepatology. GERD is a common condition

Read more

What is the Best Treatment for Esophageal Adenocarcioma?

Patients with esophageal adenocarcinoma (EAC) who receive endoscopic therapy survive as long as patients treated by surgery, according to the November issue of Clinical Gastroenterology and Hepatology. Esophageal cancer is a highly fatal malignancy—approximate 19% of patients survive 5 years. The incidence of EAC, the most common form of esophageal

Read more